Meta-analysis of belimumab versus anifrolumab in systemic lupus erythematosus and lupus nephritis
Belimumab and anifrolumab show different strengths for lupus patients
This meta-analysis compared belimumab and anifrolumab using indirect evidence from randomized controlled trials involving 4332 patients with…
A new analysis compares two lupus drugs. Belimumab worked better for overall disease control, while anifrolumab helped lower steroid doses a…
Meta-analysis links CYP2C19*2 polymorphism to reduced cyclophosphamide toxicity in SLE
Genetic marker may lower risk of cyclophosphamide toxicity in lupus patients
This meta-analysis of 5 observational studies found that the CYP2C19*2 genetic polymorphism is associated with a protective effect against…
A genetic variant linked to lower risk of cyclophosphamide side effects in lupus patients, though evidence remains limited by small study si…
Systematic Review Links Lysosomal Pathways to Autoimmune Kidney Disease Progression
Lysosomal pathways may control autoimmune kidney disease progression
This systematic review synthesizes evidence that lysosomal functions act as checkpoints in autoimmune kidney diseases like lupus nephritis a…
New evidence suggests that targeting lysosomal functions could offer a new way to manage serious autoimmune kidney diseases.
Mini Review Covers Complement Pathways in Kidney Diseases and Injuries
Review offers overview of kidney disease treatments and risks
This mini review examines the role of complement-mediated mechanisms across multiple renal pathologies without specific outcome data.
This mini review summarizes current knowledge on kidney conditions like lupus nephritis and transplant care, offering a broad look at the fi…
Rituximab pharmacokinetics vary widely in membranous nephropathy, minimal change disease, and lupus nephritis patients
Rituximab Works — But Only If Your Body Keeps Enough of It
This review examined pharmacokinetic profiling of rituximab in patients with glomerular diseases.
Rituximab helps kidney disease patients only if their bodies keep enough of it in the blood, since some people clear the drug too fast and g…
Retrospective Analysis of Repeat Kidney Biopsy Outcomes in 19 Pediatric Lupus Nephritis Patients
Small study examines repeat kidney biopsies in children with lupus nephritis
This retrospective cohort study evaluated 19 pediatric lupus nephritis patients aged 5 to 18 years at Nanjing Children's Hospital between 20…
A small study of 19 children with lupus nephritis shows how repeat kidney biopsies track disease changes over time to guide future treatment…
LOC100130476 rs80213143 variant associated with SLE susceptibility and renal involvement in Chinese Han cohort
Genetic variant linked to lupus susceptibility and kidney involvement in Chinese study
A cohort study in a Chinese Han population found the rs80213143 variant at LOC100130476 was associated with systemic lupus erythematosus sus…
A specific genetic marker found in Chinese patients is strongly linked to lupus and predicts more severe kidney disease.
Review examines glucose metabolic reprogramming in SLE and lupus nephritis pathogenesis
Review explores how sugar metabolism changes might fuel lupus immune system problems
A systematic review synthesizes evidence on glucose metabolic reprogramming in immune cells in systemic lupus erythematosus and lupus nephri…
Lupus immune cells change how they use sugar for energy, a shift that drives the disease and kidney damage, opening doors to new metabolic t…
Phase 3 Trial of Cenerimod for Lupus Nephritis: Efficacy and Safety Evaluation
Could a New Drug Help Improve Kidney Function in Lupus Patients?
A Phase 3 trial is assessing cenerimod's efficacy and safety in treating active lupus nephritis. The primary endpoint is complete renal resp…
A new trial tests whether adding cenerimod to regular treatment can improve kidney function in adults with active lupus nephritis over 76 we…
Research across Systemic Lupus Erythematosus
Related studies from across the Systemic Lupus Erythematosus family.
Deep learning models show high sensitivity and specificity for SLE and lupus nephritis diagnosis
Machine Learning Models Show Promise for Diagnosing Lupus Conditions
This meta-analysis of 29 studies evaluated the diagnostic performance of machine learning and deep learning models for SLE, lupus nephritis,…
New analysis shows deep learning models may offer high accuracy in identifying various types of lupus and related kidney or neurological con…
Voclosporin doubles proteinuria reduction in lupus nephritis but raises adverse events
Voclosporin Shows Better Results for Lupus Nephritis Protein Reduction
This meta-analysis of randomized controlled trials in 770 adults with lupus nephritis found that adding voclosporin to standard treatment si…
Adding voclosporin to standard treatment may help reduce protein in the urine for adults with Lupus Nephritis, though it carries higher safe…
No direct evidence exists regarding altered ncRNA levels in breast milk from mothers with SLE
Breast Milk RNA in Lupus Mothers: What We Know
This literature review examines the presence of ncRNA molecules in human breast milk and their potential impact on the neonatal immune syste…
A review finds no direct proof that lupus changes RNA in breast milk, but highlights the need for more research on infant immunity.
High disease activity in paediatric SLE is associated with increased risk of multisystem involvement
High disease activity linked to organ damage in children with lupus
This meta-analysis of 4934 paediatric patients with systemic lupus erythematosus (pSLE) indicates that high disease activity is associated w…
Children with high disease activity in lupus are much more likely to experience serious complications like kidney damage and neurological is…
Obinutuzumab improves SRI-4 response by 23.1 percentage points in active systemic lupus erythematosus
Trial shows obinutuzumab improves outcomes for systemic lupus erythematosus
This Phase 3 randomized controlled trial of 303 adults with active systemic lupus erythematosus found obinutuzumab significantly superior to…
A new clinical trial shows that obinutuzumab significantly improved response rates for adults with active systemic lupus erythematosus compa…
Aortic root and coronary ostium involvement in Libman-Sacks endocarditis: a rare case
Rare Heart Complications Found in Patient with Lupus and Syndrome
This case report describes a 25-year-old woman with systemic lupus erythematosus and antiphospholipid syndrome who developed Libman-Sacks en…
A single case report reveals a patient with lupus and antiphospholipid syndrome who developed a rare, life-threatening heart valve obstructi…
Chemokine network emerges as rational lupus nephritis target as standard therapy fails 30% to 40%
Chemokine Networks May Offer New Targets for Lupus Nephritis
This systematic review synthesizes evidence on the chemokine network in lupus nephritis, highlighting its role in driving immune cell infilt…
New research identifies the chemokine system as a potential target to improve treatment for patients with lupus nephritis and systemic lupus…
High-risk APOL1 genotypes more than double odds of lupus nephritis ESRD
High Risk APOL1 Genotypes Linked to Kidney Damage in Lupus
This meta-analysis of 1,885 patients of African ancestry with systemic lupus erythematosus found that high-risk APOL1 genotypes were associa…
A specific genetic marker called APOL1 may signal an increased risk of end-stage renal disease for patients with lupus and kidney involvemen…
CAR T-cell therapy targeting CD19 or BCMA may induce sustained remission in specific autoimmune diseases
CAR T-cell Therapy Shows Potential for Autoimmune Disease Remission
This systematic review examines CAR T-cell therapies for patients with systemic lupus erythematosus, idiopathic inflammatory myopathy, and s…
A new type of cell therapy may offer a way to reset the immune system in patients with lupus, scleroderma, and inflammatory myopathy.
Seven genome-wide significant loci and eight HLA alleles associated with shingles susceptibility identified
Genetic Links Connect Shingles to Stroke and Lupus Risk
This meta-analysis of a large genome-wide association study identifies seven genomic loci, including IGHG1 and IFNAR2, linked to shingles. M…
New research identifies specific genetic markers for shingles and suggests a potential link between the virus and conditions like stroke and…
Mucocutaneous manifestations serve as diagnostic indicators for various systemic diseases and paraneoplastic syndromes
Skin and Mouth Signs May Signal Serious Internal Diseases
This narrative review synthesizes the clinical significance of mucocutaneous signs as indicators for conditions including SLE, dermatomyosit…
Certain skin and mouth changes can serve as important clues for doctors to identify underlying conditions like lupus, infections, and metabo…
Meta-analysis identifies 101 genetic risk loci including 12 novel sites for systemic lupus erythematosus
Genetic study finds 12 new lupus risk genes
This meta-analysis of multi-ancestry individuals identified 101 risk loci, including 12 novel ones, associated with systemic lupus erythemat…
A large genetic study uncovered 12 new lupus risk genes, offering clues for future treatments and drug repurposing.
Questions about Lupus Nephritis
Do complement pathways cause kidney injuries in patients with lupus nephritis?
Yes, complement pathways — especially the classical and alternative pathways — contribute to kidney injury in lupus nephritis by driving inflammation and tissue damage after immune complex deposition.
Full answer →Is there a genetic variant linked to lupus nephritis risk in Chinese Han populations?
Yes, the rs80213143 variant in LOC100130476 is linked to lupus nephritis risk in Chinese Han populations, with the C allele associated with more severe kidney involvement.
Full answer →What role do lysosomal pathways play in the progression of autoimmune kidney disease like lupus nephritis?
Lysosomal pathways act as checkpoints that regulate immune activation, autoantigen processing, and metabolic-immune crosstalk, driving lupus nephritis progression.
Full answer →Does having the CYP2C19*2 gene variant protect against cyclophosphamide side effects in lupus nephritis?
Yes, the CYP2C19*2 variant is linked to reduced cyclophosphamide toxicity in lupus nephritis, based on a meta-analysis showing a protective effect.
Full answer →How does belimumab compare to anifrolumab for treating lupus nephritis?
Belimumab is approved for lupus nephritis and appears more effective than anifrolumab, which is not yet approved for this condition.
Full answer →